NCT06208930

Brief Summary

The exploration of the safety and efficacy of fecal microbiota transplantation in the treatment of non-digestive system diseases associated with gastrointestinal symptoms in the gastrointestinal tract, while also investigating the impact of fecal microbiota transplantation on the intestinal system, and assessing the improvement of symptoms in other systems.Simultaneously optimizing the conditions during the FMT process, identifying the most effective treatment methods to enhance the therapeutic outcomes of FMT.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10,000

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2018

Completed
6 years until next milestone

First Submitted

Initial submission to the registry

January 7, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 17, 2024

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 10, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2025

Completed
Last Updated

January 24, 2024

Status Verified

January 1, 2024

Enrollment Period

7.9 years

First QC Date

January 7, 2024

Last Update Submit

January 23, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Comparing the therapeutic efficacy of patients after FMT.

    Through conducting relevant questionnaire surveys with patients, we can gain insights into the therapeutic efficacy of patients after undergoing FMT.

    0day, 7days, 30days, 3 months, 6months,12 months

  • Comparing the differences in microbiota composition in samples such as feces and small intestinal fluid from patients.

    Performing 16S rRNA sequencing, metagenomic sequencing, and metabolite analysis on the samples.

    0day, 7days, 30days, 3 months, 6months,12 months

Study Arms (1)

FMT group

EXPERIMENTAL
Procedure: Fecal microbiota transplantation

Interventions

Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.

FMT group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Being able to tolerate a nasoenteric tube or swallow a capsule.

You may not qualify if:

  • Intestinal barrier dysfunction. Inability to tolerate enteral nutrition.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Le Wang

Shanghai, Shanghai Municipality, 200040, China

RECRUITING

MeSH Terms

Interventions

Fecal Microbiota Transplantation

Intervention Hierarchy (Ancestors)

Biological TherapyTherapeutics

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dean of the hospital

Study Record Dates

First Submitted

January 7, 2024

First Posted

January 17, 2024

Study Start

January 10, 2018

Primary Completion

December 10, 2025

Study Completion

December 10, 2025

Last Updated

January 24, 2024

Record last verified: 2024-01

Locations